Paul S. Herendeen
2019 - Valeant Pharmaceuticals International
In 2019, Paul S. Herendeen earned a total compensation of $7M as Former Executive Vice President and Chief Financial Officer at Valeant Pharmaceuticals International, a 9% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,728,000 |
|---|---|
| Option Awards | $1,050,049 |
| Salary | $1,000,000 |
| Stock Awards | $3,175,712 |
| Other | $23,600 |
| Total | $6,977,361 |
Herendeen received $3.2M in stock awards, accounting for 46% of the total pay in 2019.
Herendeen also received $1.7M in non-equity incentive plan, $1.1M in option awards, $1M in salary and $23.6K in other compensation.
Rankings
In 2019, Paul S. Herendeen's compensation ranked 1,381st out of 13,971 executives tracked by ExecPay. In other words, Herendeen earned more than 90.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,381 out of 13,971 | 90th |
Division Manufacturing | 485 out of 5,701 | 92nd |
Major group Chemicals And Allied Products | 145 out of 2,200 | 93rd |
Industry group Drugs | 116 out of 1,886 | 94th |
Industry Pharmaceutical Preparations | 87 out of 1,398 | 94th |
Source: SEC filing on May 2, 2022.
Herendeen's colleagues
We found three more compensation records of executives who worked with Paul S. Herendeen at Valeant Pharmaceuticals International in 2019.